Reuters logo
Sinovac vaccine meets main goal of late-stage study
March 14, 2013 / 10:56 AM / 5 years ago

Sinovac vaccine meets main goal of late-stage study

March 14 (Reuters) - China-based Sinovac Biotech Ltd said a late-stage trial of its experimental vaccine for hand, foot and mouth disease met the main study goal of preventing the infection in infants between the ages of 6 and 35 months.

The vaccine, Enterovirus 71 (EV71), showed 95.4 percent efficacy against the disease.

Hand, foot and mouth disease is a viral illness that usually affects infants and children younger than five years old.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below